Clinical Trial Detail

NCT ID NCT01587703
Title A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

lung non-small cell carcinoma

neuroblastoma

lung small cell carcinoma

colorectal cancer

triple-receptor negative breast cancer

multiple myeloma

NUT midline carcinoma

prostate cancer

estrogen-receptor positive breast cancer

Advanced Solid Tumor

Therapies

Molibresib

Age Groups: adult senior child

No variant requirements are available.